Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
CBA Posts Record A$10.98B Profit Despite Cautious Outlook 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
Add as a preferred source on Google
Merck & Co. Inc. is buying Caraway Therapeutics for a potential sum of up to $610 million. The New Jersey-based company confirmed this deal on Tuesday, Nov. 21.
Reuters reported that Merck will acquire the said biotech firm through a subsidiary. The upfront payment will be offset by the company in the last quarter of this year.
Other Details of the Deal
Merck signed off on a contract for the acquisition of Caraway Therapeutics which was originally named Rheostat Therapeutics. In addition to the upfront, Merck will complete the payment via milestones. At this point, there are no details about the breakdown of the exact costs yet.
The transaction was already approved by Caraway’s Board of Directors. The firm is known for its experimental treatment of genetically defined neurodegenerative conditions and other rare diseases such as Parkinson's disease.
The Future of the Partnership
Merck and Caraway Therapeutics are both looking forward to joint efforts in the development of better treatments for neurodegenerative diseases. At any rate, under the terms of their acquisition deal, the former, through its subsidiary, will buy all outstanding shares of Caraway with earnout milestones related to the development of some pipeline candidates.
“Caraway’s multidisciplinary approach has yielded important progress in evaluating novel mechanisms of modulation of lysosomal function with potential for the treatment of progressive neurodegenerative diseases,” Merck Research Laboratories’ senior vice president of discovery, preclinical development and translational medicine, George Addona, said in a press release. “We look forward to applying our expertise to build upon this work with the goal of developing much-needed disease-modifying therapies for these conditions.”
Caraway Therapeutics’ chief executive officer, Martin D. Williams, added that the deal with Merck is an important milestone for the company. Furthermore, he said the acquisition is also a testament to the dedication and hard work of the Caraway team that tried its best to fulfill the company’s mission of creating therapeutics with the “potential to alter the progression of devasting neurodegenerative diseases and help patients.”
Williams went on to say, “This acquisition leverages Merck’s industry-leading research and development capabilities to help further advance our discovery and preclinical programs. We thank and appreciate our investors, including SV Health Investors and its Dementia Discovery Fund, AbbVie Ventures, Amgen Ventures, Eisai Innovation and MRL Ventures Fund for their support.”
Photo by: Merck Media Library
